CoTherix

CoTherix, Inc.
Subsidiary
Industry Pharmaceutical
Fate acquired by Actelion
Founded 2000
Defunct January 9, 2007 (2007-01-09)
Headquarters South San Francisco, California
Key people
Donald J. Santel, CEO & Director
Products Ventavis
Revenue $63 million USD
Number of employees
100
Slogan Developing and Commercializing New Therapies for Life-Threatening Diseases.
Website www.cotherix.com

CoTherix, Inc. was a biopharmaceutical company located in South San Francisco, California. CoTherix focused on licensing, developing, and commercializing therapeutic products for the treatment of cardiopulmonary and other chronic diseases. The company, formerly known as Exhale Therapeutics, Inc., was founded in February 2000 by Gerard Turino, MD, a past president of the American Thoracic Society, and Jerome Cantor, MD, a pulmonary pathologist.

CoTherix's commercial product was "Ventavis (Iloprost)", an inhaled therapy for pulmonary artery hypertension (PAH). It was approved by the United States Food and Drug Administration in December 2004, two months after the company's initial public offering of 5 millions shares of common stock.

CoTherix inlicensed Fasudil from Asahi Kasei and its commercialization rights in the U.S. and Europe.

On November 20, 2006, CoTherix agreed to be purchased for $420 million in cash by Actelion of Basel, Switzerland. On January 9, 2007, the deal closed with Actelion paying $13.50 for each share of CoTherix stock.

External links

This article is issued from Wikipedia - version of the Saturday, April 25, 2015. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.